Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

Alocril now available in U.S. for itch associated with allergic conjunctivitis

March 2, 2000

Santen seeks FDA approval of levofloxacin for bacterial conjunctivitis

March 1, 2000

Allergan and Dura enter commercialization agreement for multiple products

Feb. 25, 2000

GenVec licenses gene for treating blindness

Feb. 24, 2000

Oxigene to develop CA4P for eye, skin and joint disorders

Feb. 23, 2000

New selectin inhibitor SKK-60060 shows promise in treatment of uveitis

Feb. 22, 2000

Blockade of VEGF alone is sufficient to prevent blinding illness

Feb. 21, 2000

Novel Merck compounds inhibit KDR kinase and VEGF activity

Feb. 15, 2000

Ophthalmic antibacterial on the way to market in Japan

Feb. 15, 2000

FDA issues approvable letter for Visudyne

Feb. 14, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...